Impact Biomedical Inc. IBO
- Market cap
- $48.3M
- P/E
- 6.5×
Follow IBO
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 14.68 | 4.58 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 41.14 | 78.10 |
High Price
|
|||
| — | — | — | — | — | — | — | 5 | 8 | 8 |
Employees
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | 0 | — | — | 0 |
Revenue
|
|||
| — | — | — | — | — | — | 100.00% | — | — | (1,225.00%) |
Gross Margin
|
|||
| — | — | — | — | — | — | (8) | (4) | (25) | (14) |
EBT
|
|||
| — | — | — | — | — | — | (15,752.00%) | 0.00% | 0.00% | (45,156.25%) |
EBT Margin
|
|||
| — | — | — | — | — | — | (7) | (4) | (25) | (12) |
Net Income
|
|||
| — | — | — | — | — | — | 1 | 1 | 26 | 1 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | (0.10) | (0.07) | (2.30) | (0.38) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | (0.03) | (0.05) | (0.27) | (0.06) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | (0.04) | (0.05) | (0.27) | (0.06) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | 0.46 | 0.47 | 0.67 | 0.49 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 70 | 60 | 11 | 32 |
Shares
|
|||
| — | — | — | — | — | — | 0.00 | — | — | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | 0.00 | — | — | 2,458.59 |
PS Ratio
|
|||
| — | — | — | — | — | — | 12.88 | — | — | 12.96 |
PB Ratio
|
|||
| — | — | — | — | — | — | 0.00 | — | — | 2,555.76 |
EV/Sales
|
|||
| — | — | — | — | — | — | (170.49) | — | — | (109.84) |
EV/FCF
|
|||
| — | — | — | — | — | — | (2) | (3) | (3) | (2) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | 0 | 0 | — | — |
Capex
|
|||
| — | — | — | — | — | — | (3) | (3) | (3) | (2) |
FCF
|
|||
| — | — | — | — | — | — | (10) | (13) | (7) | (1) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | 0 | 0 | (2) | 0 |
Net Debt
|
|||
| — | — | — | — | — | — | 33 | 28 | 7 | 16 |
Sh' Equity
|
|||
| — | — | — | — | — | — | 0.00% | (9.52%) | (76.11%) | (62.81%) |
ROA
|
|||
| — | — | — | — | — | — | (6.51%) | (8.91%) | (343.08%) | (17.21%) |
ROIC
|
|||
| — | — | — | — | — | — | 0.00% | (14.25%) | (139.68%) | (104.15%) |
ROE
|
|||
Impact Biomedical Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TIL Instil Bio, Inc. | $48.3M | 0.0× | Compare |
| DWTX Dogwood Therapeutics, Inc | $48.6M | 0.0× | Compare |
| HOWL Werewolf Therapeutics, Inc. | $47.7M | 0.0× | Compare |
| LITS Lite Strategy, Inc. | $51.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TVGN Tevogen Inc. | $51.1M | 0.0× | Compare |
| GRCE Grace Therapeutics, Inc. | $45.4M | 0.0× | Compare |
| PDSB PDS Biotechnology Corporation | $44.2M | 0.0× | Compare |
| IMA ImageneBio, Inc. | $52.9M | 0.0× | Compare |
Impact Biomedical Inc. (IBO) key facts
- Impact Biomedical Inc. (IBO) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022.
- As of September 25, 2026, IBO traded at $5.69, a market capitalization of $48.3 million.
- Return on equity was −104.2% and debt-to-equity 0.00.
Impact Biomedical Inc. (IBO) Latest News
16 Sep
DSS, Inc. filed Form F-4 with the SEC regarding Impact Biomedical Inc.'s proposed business combination with Zoar Limited. Proposed business combination filing marks a major strategic corporate restructuring for Impact Biomedical.
Impact Biomedical Inc. filed a Form F-4 registration statement in connection with its proposed merger with Zoar Ltd., formerly known as Dr. Ashley’s Limited. Merger filing marks major strategic move with potential to significantly reshape company operations and market position.
DSS, Inc. celebrates Impact BioMedical Inc.'s successful IPO at $3.00 per share with 1,500,000 shares, enhancing shareholder value. The successful IPO and pricing at $3.00 per share is a significant strategic move that is expected to fundamentally alter Impact BioMedical Inc.'s trajectory and investor sentiment.
Impact BioMedical Inc. priced its initial public offering of 1,500,000 shares at $3.00 per share, with trading expected to start on September 16, 2024. The pricing of the IPO and potential underwriter warrants could have a significant impact on Impact BioMedical Inc.'s future financial performance and market positioning.
14 Sep
Impact Biomedical Inc (NYSE: IBO) announces 1 for 12.62 reverse stock split to complete merger with Zoar Limited (f/k/a Dr Ashleys Limited). Reverse stock split enables merger completion and may significantly alter company trajectory.
11 Sep
Impact Biomedical Inc. (IBO) will execute a 1 for 12.62 reverse stock split to enable completion of its merger with Zoar Ltd., formerly Dr. Ashley’s Ltd. Reverse stock split execution directly advances a merger that may significantly alter company structure and market trajectory.
3 Apr
Impact Biomedical Inc. (IBO) reported a going concern audit opinion in its 2025 10-K filing, indicating substantial doubt about its ability to continue operations without additional funding, while continuing to advance strategic merger plans. Going concern opinion signals severe financial distress and erodes investor confidence, potentially derailing merger plans and market performance.
18 Aug
Impact Biomedical Inc. (IBO) has announced the issuance of a US patent for its 3F™ technology, which is designed to enhance the delivery of therapeutic agents. This patent is expected to strengthen the company's intellectual property portfolio and potentially improve its competitive position in the biomedical field. The 3F™ technology aims to address significant challenges in drug delivery, which could lead to advancements in treatment efficacy and patient outcomes. The issuance of a patent for a novel technology can significantly enhance the company's competitive position and market potential.
23 Jun
Dr Ashleys Limited and Impact Biomedical Inc. have announced a strategic merger aimed at enhancing their market presence and operational capabilities. The merger is expected to create synergies that will benefit both companies, allowing for improved resource allocation and innovation in their respective fields. This collaboration is anticipated to strengthen their competitive positioning and drive growth in the biomedical sector. The merger is a significant strategic move that could alter the company's trajectory and investor sentiment.
Impact Biomedical Inc. (IBO) has seen a notable increase in its stock price, making it one of the top midday gainers. The surge in share value is attributed to positive market sentiment and potential developments in the company's operations. Investors are closely monitoring IBO's performance as it navigates current market conditions. The stock price increase indicates moderate investor interest, but it is not expected to fundamentally alter the company's trajectory.
21 Mar
Impact Biomedical Inc. (IBO) experienced a significant surge in stock price on Thursday, driven by positive developments in its research initiatives and strategic partnerships aimed at advancing its biomedical technologies. The company announced promising results from recent studies, which have garnered investor interest and confidence in its future prospects. Additionally, collaborations with key industry players have positioned IBO favorably within the competitive landscape, further contributing to the stock's upward momentum. Recent positive research results and strategic partnerships are likely to significantly impact the company's future performance and investor sentiment.
Impact Biomedical Inc. (IBO) has announced recent stock activity and pricing updates, reflecting changes in market dynamics and investor interest. The company is actively engaging with stakeholders to enhance its market presence and operational strategies. These developments may influence future trading patterns and investor sentiment towards IBO. Recent stock activity and pricing updates may moderately influence investor sentiment and trading patterns.
26 Feb
Impact Biomedical Inc. has announced the acquisition of Celios®, a company focused on enhancing air quality in clean-room environments to protect against dangerous pathogens affecting people, plants, and animals. This strategic move aims to bolster Impact Biomedical's capabilities in pathogen control and improve its market position in health and safety solutions. The acquisition of Celios® is a significant strategic move that could enhance product offerings and market positioning in pathogen control.
DSS, Inc. has sold its Celios® air purification asset to Impact BioMedical Inc. in an all-equity transaction valued at approximately $1.15 million. This divestiture is part of DSS' strategy to streamline its portfolio and focus on core growth areas. Celios® features a patented three-stage filtration system designed to improve indoor air quality. DSS believes that Impact BioMedical is well-positioned to leverage this technology, allowing DSS to concentrate on high-impact investments in other sectors. The acquisition of Celios® is expected to enhance Impact BioMedical's product offerings and market positioning, but its overall effect on the company's trajectory remains limited.
23 Jan
Impact Biomedical Inc. will present at The Microcap Conference, showcasing its advancements and strategic initiatives to potential investors. The conference aims to connect emerging companies with investors, providing a platform for networking and investment opportunities. Impact Biomedical's participation highlights its commitment to growth and visibility in the market. Participation in investor conferences can moderately influence market sentiment and visibility, potentially impacting future financial performance.
19 Nov
Impact BioMedical Inc. issues shareholder letter highlighting recent achievements and strategic vision. The shareholder letter may moderately influence key areas such as financial performance and competitive positioning.
15 Oct
Impact BioMedical Inc. receives Canadian patent for Linebacker™ technology targeting inflammatory diseases. The issuance of the Canadian patent for Linebacker™ technology is a significant development that can potentially impact the company's future market performance and competitive positioning.
7 Oct
Impact BioMedical Inc. (NYSE American: IBO) announces successful completion of IPO with strong support from existing investors. Successful IPO with strong investor support is likely to have a significant impact on the company's future trajectory and market performance.
26 Sep
Impact BioMedical Inc. announces the issuance of a new US patent for insect repelling composition developed within their 3F™ technology platform, expanding their patent estate. The issuance of a new patent for insect repelling composition has the potential to significantly impact Impact BioMedical Inc.'s future market performance and competitive positioning.
23 Sep
Impact BioMedical Inc. introduces new leadership team to drive innovation and growth in the healthcare industry. The introduction of an experienced leadership team is expected to have a significant impact on the company's future growth and performance.
17 Sep
Impact BioMedical Inc. closed its initial public offering of 1,500,000 shares at $3.00 per share, with additional shares available for purchase. The company's shares began trading on the NYSE American Market under the ticker symbol 'IBO'. The closing of the IPO and shares trading on the NYSE American Market are significant events that could impact the company's future trajectory and investor sentiment.